Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury
February 27, 2024 07:25 ET
|
Arch Biopartners
TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it had a pre-investigational new drug...
Global Autoimmune Disease Therapeutics Market to 2025 - by Drug Class, Indication and Region
March 24, 2022 08:08 ET
|
Research and Markets
Dublin, March 24, 2022 (GLOBE NEWSWIRE) -- The "Global Autoimmune Disease Therapeutics Market: Analysis By Drug Class By Indication By Region Size & Trends with Impact of Covid-19 and Forecast...
Global Autoimmune Disease Therapeutics Market (2021 to 2025) - Size & Forecast with Impact Analysis of COVID-19
February 23, 2021 08:43 ET
|
Research and Markets
Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Autoimmune Disease Therapeutics Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to...